Clinical Trial Update: A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of SAGE-547 in moderate postpartum depression completed, with results posted in June 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Depression

Drugs mentioned

• SAGE-547 (brexanolone)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Postpartum Depression | Phase 3 | Status: COMPLETED | Results posted: 2019-06-13